Armata Pharmaceuticals Reports Board Committee Assignment for Director Gilmer

What Happened

• Armata Pharmaceuticals, Inc. filed a Form 8‑K on June 24, 2026 (Accession No. 0001104659-26-077313) under Item 5.02 disclosing the board committee assignments for director Gilmer. The filing reports governance information about Gilmer’s roles on the company’s board committees.

Key Details

• Filing: Form 8‑K filed June 24, 2026 (Item 5.02).
• Subject: Disclosure of director Gilmer’s board committee assignments.
• Company/Ticker: Armata Pharmaceuticals, Inc. (ARMP).
• Accession Number: 0001104659-26-077313.

Why It Matters

• Committee assignments tell investors which board committees (for example, audit, compensation, or nominating/governance) a director will serve on, which affects oversight responsibilities and governance structure.
• This is a routine SEC governance disclosure — useful for shareholders tracking board composition and who is responsible for key oversight areas, but the filing does not indicate changes to executive employment or financial statements.